Aurinia Pharmaceuticals Inc. announced that for fiscal year 2022, the Company is providing net revenue guidance of $115 million to $135 million from sales of LUPKYNIS. This range is based on assumptions regarding the impact of COVID-19 on the current business environment and represents an increase of more than 150% to 200% in net revenue from sales of LUPKYNIS compared to fiscal year 2021.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.27 USD | -1.68% | -0.38% | -41.38% |
12:24pm | Aurinia Pharmaceuticals Inc. Presents Safety and Efficacy Profile of LUPKYNIS® for People with Lupus Nephritis | CI |
03/06 | Lucien Selce Sends Letter to Aurinia shareholders | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-41.38% | 75Cr | |
+16.73% | 12TCr | |
+13.04% | 11TCr | |
-5.80% | 2.4TCr | |
+3.03% | 2.26TCr | |
-10.09% | 1.82TCr | |
-40.52% | 1.68TCr | |
-14.00% | 1.62TCr | |
+1.18% | 1.34TCr | |
+24.18% | 1.13TCr |
- Stock Market
- Equities
- AUPH Stock
- News Aurinia Pharmaceuticals Inc.
- Aurinia Pharmaceuticals Inc. Provides Revenue Guidance for the Year 2022